Clayton Utz has been appointed as legal adviser to the NSW Government in its public private partnership to finance, design and build 498 new train carriages. The estimated $1.5 billion Rail Corp project aims to replace all existing, non-air conditioned carriages by 2010. The appointment follows previous advisory roles to the (then) State Rail Authority (now Rail Corp) for its previous new train procurements — the Millennium, Hunter Cars and Outer Suburban Cars.
Skadden is representing Mylan Laboratories Inc., a leading Pennsylvania-based pharmaceutical company, in its approximately US$4.2 ($5.8) billion acquisition of King Pharmaceuticals, Inc., a Tennessee-based branded pharmaceutical company. When the acquisition is complete, Mylan shareholders will own approximately 56 percent of the company’s outstanding shares, and King will own approximately 44 percent. The firm said the acquisition would create the US’s leading diversified specialty pharmaceutical company and the country’s second largest pharmaceutical company based on the number of US prescriptions dispensed.